摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexanoic acid | 92518-35-9

中文名称
——
中文别名
——
英文名称
6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexanoic acid
英文别名
6-(4-acetyl-3-hydroxy-2-propylphenoxy)caproic acid
6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexanoic acid化学式
CAS
92518-35-9
化学式
C17H24O5
mdl
——
分子量
308.375
InChiKey
BNQMUKPUYBDCAY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    63-64 °C
  • 沸点:
    510.1±50.0 °C(Predicted)
  • 密度:
    1.142±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    22
  • 可旋转键数:
    10
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    83.8
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(吡啶-4-基硫烷基)-乙胺6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexanoic acidethyl acetate n-hexane 作用下, 以to give 6-(4-acetyl-3-hydroxy-2-propylphenoxy)-N-[2-(4-pyridinylthio)ethyl]hexanamide的产率得到6-(4-acetyl-3-hydroxy-2-propylphenoxy)-N-[2-(4-pyridinylthio)ethyl]hexanamide
    参考文献:
    名称:
    Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
    摘要:
    本发明涉及一种公式为##STR1##的化合物,其中R为氢或低级烷基,Y为烷基;Z为烷基,##STR2##此处星号表示与取代的乙酰苯酮结合;R.sub.2为氢或低级烷氧基;n为1至3的整数;A为##STR3##,HET为含有5或6个成员的氮杂环异构基团,以及它们的酸加成盐。本发明的I型化合物可用于治疗过敏症,如哮喘和心血管疾病,如心绞痛和心律失常。
    公开号:
    US04672066A1
  • 作为产物:
    描述:
    6-溴己酸三乙基硅烷甲酸三氟化硼乙醚potassium carbonate 、 potassium iodide 作用下, 以 二氯甲烷丙酮 为溶剂, 反应 66.0h, 生成 6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexanoic acid
    参考文献:
    名称:
    Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives
    摘要:
    A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.
    DOI:
    10.1021/jm00387a018
点击查看最新优质反应信息

文献信息

  • Substituted 4-acetyl-3-hydroxyphenoxy alkanoic acids
    申请人:Hoffmann-La Roche Inc.
    公开号:US04628115A1
    公开(公告)日:1986-12-09
    The invention relates to compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl, Z is alkylene of 1 to 10 carbon atoms, --(C*H.sub.2).sub.3 --C.tbd.C--, --C*H.sub.2 --C.tbd.C--(CH.sub.2).sub.3 --, and --(CH.sub.2).sub.2 O].sub.n (CH.sub.2).sub.2 -- wherein n is an integer of 1 to 3, the carbon atom marked with an asterisk is linked to the phenoxy moiety, and salts thereof with pharmaceutically acceptable bases. The compounds of formula I are antagonists of slow reacting substance of anaphylaxis (SRS-A; leukotrienes C.sub.4, D.sub.4 and E.sub.4), which renders them useful as agents for the treatment of allergic conditions.
    该发明涉及以下式的化合物##STR1##其中R是氢或较低的烷基,Z是1至10个碳原子的烷基,--(C*H.sub.2).sub.3 --C.tbd.C--, --C*H.sub.2 --C.tbd.C--(CH.sub.2).sub.3 --,以及--(CH.sub.2).sub.2 O].sub.n (CH.sub.2).sub.2 --其中n是1至3的整数,带有星号标记的碳原子与苯氧基团连接,并且其与药学上可接受的碱盐。式I的化合物是过敏反应缓慢反应物(SRS-A;白三烯C.sub.4,D.sub.4和E.sub.4)的拮抗剂,使它们在过敏症状治疗剂方面有用。
  • Phenoxyacetic acid compounds and medical preparations containing them
    申请人:TERUMO KABUSHIKI KAISHA
    公开号:EP0562796A1
    公开(公告)日:1993-09-29
    Disclosed are phenoxyacetic acid compounds of formula (I): where X is a hydrogen atom, a lower alkyl group or a halogen atom; R1 is a carboxyl group or a lower alkoxycarbonyl group; Y is an oxygen atom, or n is an integer of from 0 to 5; Z is or R2 is a hydrogen atom or a lower alkyl group; and m is 0 or 1. The compounds and their physiologically acceptable salts are used as thromboxane A2 antagonistic agents, leukotriene antagonistic agents and/or anti-allergic agents.
    所公开的是式 (I) 的苯氧乙酸化合物: 其中 X 是氢原子、低级烷基或卤素原子; R1 是羧基或低级烷氧羰基; Y 是氧原子、 或 n 是 0 至 5 的整数; Z 是 或 R2 是氢原子或低级烷基;以及 m 为 0 或 1。 这些化合物及其生理上可接受的盐类可用作血栓素 A2 拮抗剂、白三烯拮抗剂和/或抗过敏剂。
  • Leukotriene antagonists
    申请人:ELI LILLY AND COMPANY
    公开号:EP0108592B1
    公开(公告)日:1987-09-30
  • MARSHALL, WINSTON S.;VERGE, JOHN P.
    作者:MARSHALL, WINSTON S.、VERGE, JOHN P.
    DOI:——
    日期:——
  • MARSHALL W. S.; GOODSON T.; CULLINAN G. J.; SWANSON-BEAN D.; HAISCH K. D.+, J. MED. CHEM., 30,(1987) N 4, 682-689
    作者:MARSHALL W. S.、 GOODSON T.、 CULLINAN G. J.、 SWANSON-BEAN D.、 HAISCH K. D.+
    DOI:——
    日期:——
查看更多